~~<i id='F85597C822'><strike id='F85597C822'><tt id='F85597C822'><pre id='F85597C822'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

author：entertainment 2025-09-30 01:02:13 - browse：77

An advisory panel to the Food and Drug Administration delivered a split decision on a surgical system used in a controversial blood pressure treatment called renal denervation.

The panel, whose advice the FDA typically follows, voted that the system developed by ReCor Medical was safe and effective. It voted that the benefits of a system developed by Medtronic, however, did not outweigh the risks.

“While this is a very safe procedure, the efficacy was mild at best,” Keith Allen, director of surgical research at St. Luke’s Hospital of Kansas City, said regarding Medtronic’s device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： What is the Turing Test that determines if computers can think?

focus

knowledge

leisure time

explore

AdobeThehealthrecordscompanyNextGenHealthcarewillpay$31milliontoresolveallegationsthatitpaidkickback

WSS

How Medicaid coverage policies for immigrants impact new moms

Hey, doctors: Don't be no

Biden tests positive for Covid

'The View' co

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

hotspot

hotspot

focus

Drug repurposing or repositioning? The language matters

Why hospitals are withdrawing from US News rankings

New air purifier tech could be key to improving indoor air quality

It's time to take a new tack for treating Alzheimer's

Tori Bowie and the unacceptable rates of Black maternal death

'The View' co

In age of alternative facts, a scholarly course on calling out crap

What is artificial intelligence? Experts weigh in

The cancer drug shortage isn’t new — and neither are the solutions

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

focus

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

It's time to take a new tack for treating Alzheimer's

New chart reveals military’s vast involvement in Operation Warp Speed

Why hospitals are withdrawing from US News rankings

Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

focus

knowledge

leisure time

explore